William Terens, MD
Urology · Cranford, NJNPI 1013020189
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,285 of the $3,684 with a category attached, or 62.0%. 31 manufacturers reported payments, led by Johnson & Johnson at 38.1% of the total. Reporting peaked in 2020 at $1,575 and has fallen 97.9% since, to $33 in 2025.
Across 154 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Astellas Pharma US Inc$734
- Pfizer$286
- Procept Biorobotics Corporation$139
- Endo Pharmaceuticals Inc.$137
- Dendreon Pharmaceuticals LLC$106
- plus $877 from 25 others
Across 4 payments — averaging $432.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acerus Pharmaceuticals Corporation$2K
What the payments were for
- Consulting fees$1,01027%
- Food & beverage$2,28562%
- Education$38911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 25 | $1,405 |
| Astellas Pharma US Inc | 37 | $734 |
| Pfizer | 21 | $286 |
| Procept Biorobotics Corporation | 2 | $139 |
| Endo Pharmaceuticals Inc. | 10 | $137 |
| Dendreon Pharmaceuticals LLC | 5 | $106 |
| Myovant Sciences Inc. | 6 | $84 |
| Boston Scientific | 3 | $74 |
| Bayer | 3 | $62 |
| Amgen | 4 | $59 |
| AbbVie(2 entities) | 4 | $57 |
| Myriad Genetic Laboratories, Inc. | 4 | $56 |
| Medtronic | 3 | $52 |
| Antares Pharma, Inc. | 1 | $50 |
| AstraZeneca | 3 | $44 |
| Acerus Pharmaceuticals Corporation | 3 | $39 |
| Olympus America Inc. | 2 | $34 |
| Merck | 2 | $30 |
| Verity Pharmaceuticals Inc. | 2 | $30 |
| Tolmar Pharmaceuticals, Inc. | 2 | $27 |
| Rochester Medical Corporation | 1 | $24 |
| Aytu Biopharma, Inc. | 2 | $24 |
| Hollister Incorporated | 1 | $19 |
| Mission Pharmacal Company | 1 | $15 |
| Teleflex LLC | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $14 |
| 180 Medical, Inc. | 1 | $14 |
| Coloplast | 1 | $13 |
| Ambu Inc. | 1 | $12 |
| Blue Earth Diagnostics | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$1,010
- AquaBeam Robotic System$122
How this compares
$3,684 in reported general payments places this provider in the 65th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 28 | $373,509 |
| XtandiEnzalutamide | 19 | $273,697 |
| MyrbetriqMirabegron | 200 | $191,542 |
| GemtesaVibegron | 37 | $35,988 |
| Tamsulosin Hcl | 1,318 | $27,262 |
| Finasteride | 1,108 | $16,763 |
| Testosterone | 107 | $16,477 |
| Desmopressin Acetate | 210 | $14,634 |
| TestopelTestosterone | 13 | $14,063 |
| Silodosin | 129 | $12,653 |
| Methenamine Hippurate | 134 | $12,496 |
| Mirabegron ErMirabegron | 11 | $10,315 |
| Tadalafil | 156 | $9,732 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 287 | $8,160 |
| Potassium Citrate ErPotassium Citrate | 69 | $7,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $734 | $465,240219 claims |
| BayerNubeqa | $62 | $373,50928 claims |
| Endo Pharmaceuticals Inc.Testopel | $137 | $14,06313 claims |
| PfizerPremarin | $286 | $7,39017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 401 urology providers in New Jersey.
Other urology in Cranford
- Mark MillerCranford$14K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.